Vericel Corp (NASDAQ:VCEL) has received a consensus rating of “Hold” from the six analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $23.31.

Several research firms have recently commented on VCEL. Zacks Investment Research downgraded Vericel from a “buy” rating to a “hold” rating in a report on Friday, March 8th. BidaskClub downgraded Vericel from a “buy” rating to a “hold” rating in a report on Friday, March 15th. Needham & Company LLC downgraded Vericel from a “buy” rating to a “hold” rating and set a $17.92 price objective for the company. in a report on Thursday, February 28th. Finally, Oppenheimer boosted their price objective on Vericel from $23.00 to $32.00 and gave the company an “outperform” rating in a report on Wednesday, May 8th.

In related news, CFO Gerard J. Michel sold 15,625 shares of Vericel stock in a transaction on Monday, April 8th. The stock was sold at an average price of $17.64, for a total transaction of $275,625.00. Following the transaction, the chief financial officer now directly owns 127,047 shares in the company, valued at $2,241,109.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Gerard J. Michel sold 10,000 shares of Vericel stock in a transaction on Monday, March 11th. The shares were sold at an average price of $20.02, for a total value of $200,200.00. Following the transaction, the chief financial officer now owns 122,249 shares in the company, valued at $2,447,424.98. The disclosure for this sale can be found here. Insiders have sold 50,625 shares of company stock valued at $899,750 in the last quarter. 4.50% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Advisory Services Network LLC lifted its holdings in Vericel by 1,400.0% during the first quarter. Advisory Services Network LLC now owns 1,500 shares of the biotechnology company’s stock worth $26,000 after buying an additional 1,400 shares during the period. Doyle Wealth Management acquired a new position in Vericel in the fourth quarter valued at approximately $35,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Vericel in the fourth quarter valued at approximately $44,000. Financial Architects Inc acquired a new position in Vericel in the fourth quarter valued at approximately $69,000. Finally, Pearl River Capital LLC acquired a new position in Vericel in the first quarter valued at approximately $72,000. Institutional investors own 85.22% of the company’s stock.

Shares of NASDAQ VCEL traded up $0.39 during midday trading on Friday, hitting $16.04. 5,123 shares of the stock traded hands, compared to its average volume of 617,180. The company has a market cap of $700.15 million, a price-to-earnings ratio of -113.89 and a beta of 2.79. Vericel has a one year low of $8.95 and a one year high of $21.00. The company has a quick ratio of 8.16, a current ratio of 8.47 and a debt-to-equity ratio of 0.24.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). The firm had revenue of $21.81 million during the quarter, compared to the consensus estimate of $22.51 million. Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The company’s quarterly revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.21) earnings per share. On average, equities research analysts anticipate that Vericel will post 0.05 earnings per share for the current year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Read More: What does a dividend yield signify to investors?

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.